The Pharma Data

NOVEMBER 14, 2020

14, 2020 — Vaping significantly increases the risk of lung disease, according to a new study that adds to growing evidence that e-cigarettes are dangerous. SATURDAY, Nov. Researchers from Boston University analyzed data gathered from more than 21,600 U.S.

Disease 52

Disease Production Research Marketing 52

FDA Law Blog: Drug Discovery

DECEMBER 13, 2023

Sasinowski — On December 12, 2023, FDA announced the creation of a new advisory committee specifically for treatments for genetic metabolic diseases, the Genetic Metabolic Diseases Advisory Committee, or “GeMDAC.” There are hundreds of known genetic metabolic diseases, most of which are rare and carry significant morbidity.

Disease 59

Disease Production FDA Drug Development 59

The Pharma Data

DECEMBER 22, 2020

Stress From Not Achieving Goals Tied to Worse Kidney Disease. from the University of Mississippi in Jackson, and colleagues explored the association between goal-striving stress (GSS) and RKFD among 2,630 African Americans using data from the Jackson Heart Study (2000 to 2004 and 2009 to 2013). Professional. TUESDAY, Dec.

Disease 52

Disease Research 52

Drug Hunter

AUGUST 21, 2023

Obtaining adequate drug exposure in the brain is key to treating CNS diseases effectively. Prodrugs Remain in “Proof-of-Concept” Stages Prodrug strategies for CNS deliver have also been applied with varying success , with the most famous example being L-Dopa for Parkinson’s disease. 2013 , 56 (1), 2-12. Figure 18. Verhoest, P.R.;

Drugs 206

Drugs Disease Targeted Protein Degradation Screening Hits 206

Broad Institute

NOVEMBER 2, 2023

We are constantly working to discover novel ways to treat this devastating disease that affects millions of people worldwide. Established in 2013, the Bayer-Broad collaboration is uniquely structured to encourage close coordination and ongoing, face-to-face interactions between researchers at both organizations.

Therapies 105

Therapies Research Small Molecule Clinical Trials 105

Drug Target Review

NOVEMBER 6, 2023

Advances in disease understanding and combination strategies in haematology We now know that blood cancers are characterised by molecular and phenotypic heterogeneity. 2013); 108(3): 479-485. 2 It is this complexity that necessitates powerful, targeted combination therapies. Cancers (Basel). 2022;14(9):2182. Published 2022 Apr 27.

Small Molecule 111

Small Molecule Therapies Treatment Disease 111

NIH Director's Blog: Drug Development

FEBRUARY 4, 2014

Recent advances in genomics, proteomics, imaging, and other technologies have led to the discovery of more than a thousand risk factors for common diseases—biological changes that ought to hold promise as targets for drugs. These three-to-five year pilot projects will set the stage for broadening AMP to other diseases and conditions.

Drug Development 52

Drug Development Disease Drugs Pharmaceuticals 52

LifeSciVC

APRIL 26, 2024

Further, this lemming challenge has also moved well beyond oncology – think of all the “not-so-fast follower” autoimmune programs or metabolic disease stories. Beyond simply backing great science (separating the wheat from the chafe), setting a company up properly is critical, and early choices can get locked into the DNA of the company.

DNA 112

DNA Science Marketing Clinical Trials 112

The Pharma Data

DECEMBER 30, 2020

Take the first disease-modifying agent approved, interferonB (Betaseron) as an example. By 2013 this had risen to $61,529, and today’s estimate is close to $66,000. And the nature of MS requires that disease-modifying treatments be started as soon as possible to ensure the best chance of forestalling relapses.

Treatment 52

Treatment FDA Approval Disease FDA 52

Drug Target Review

SEPTEMBER 26, 2023

Human derived induced pluripotent stem cells (hiPSCs) have revolutionised research and are increasingly used for toxicology screening and disease modelling. Using stem cell-derived neurons in drug screening for neurological diseases. hiPSCs for predictive modelling of neurodegenerative diseases: dreaming the possible.

Drugs 111

Drugs FDA Disease Animal Testing 111

Drug Target Review

SEPTEMBER 28, 2023

Twist was officially founded in 2013. They needed reference materials for the disease in order to develop and validate diagnostic tests. NGS tools can be used to ‘read’ DNA to identify a disease subclass and detect specific mutations. This is used in liquid biopsy and minimal residual disease (MRD) monitoring.

DNA 116

DNA Organic Chemistry Science Virus 116

PLOS: DNA Science

DECEMBER 14, 2023

It no longer fits in with a changing world, be that climate change, a novel infectious disease, mutation, a comet crash. ” The 46 granted patents begin in 2013. As a biologist, all I could think was that when an organism becomes extinct, there’s a reason. or competition from an introduced species.

DNA 119

DNA Production Science Disease 119

Broad Institute

APRIL 26, 2024

We celebrate 20 years of progress toward understanding the roots of disease and narrowing the gap between new biological insights and impact for human health. Image on the left: Eli and Edythe Broad tour the Stanley Building as it was under construction in 2013.

International 52

International Research Disease 52

The Pharma Data

JANUARY 26, 2021

Centers for Disease Control and Prevention Morbidity and Mortality Weekly Report. from the CDC in Atlanta, and colleagues updated 2013 data to examine the proportion of high school students who met the USDA recommendations for fruit and vegetable consumption. 22 issue of the U.S. Samantha J. Lange, M.P.H.,

Disease 52

Disease Research 52

Eye on FDA

JUNE 14, 2023

But the numbers began to dwindle and 2013 was the last time the office even issued 12 letters within a year (it did 23 that year). The latest letter was issued for a website that promoted a treatment for hypercortisolemia in patients with Cushings Disease. The numbers plummet in 2014 until the record low last year of only 4 letters.

FDA 82

FDA Production Doctors Treatment 82

The Pharma Data

FEBRUARY 21, 2022

Such success stories are encouraging and help us to eliminate more diseases in our Region.”. The disease. Trachoma is a devastating eye disease caused by infection with the bacterium Chlamydia trachomatis. To eliminate trachoma, WHO recommends the SAFE strategy 2 to achieve elimination of trachoma as a public health problem.

Disease 52

Disease Treatment International Drugs 52

NIH Director's Blog: Drug Development

MARCH 11, 2014

But this approach doesn’t just provide predictions of risk; it may also provide a path to developing new ways of treating and preventing this serious, chronic disease that affects about 26 million Americans. Over time, this leads to heart disease, stroke, blindness, nerve damage, kidney damage, and amputations. 2013 Aug;12(8):581-94.

DNA 52

DNA Drugs Disease Research Laboratories 52

PPD

SEPTEMBER 25, 2023

Historically, clinical trial populations were almost exclusively comprised of white, male participants,  exacerbating gaps in knowledge of diseases and conditions , preventive factors and treatment effectiveness.

Drug Development 104

Drug Development Clinical Trials Drugs Trials 104

Drug Target Review

JUNE 12, 2023

He also pioneered applications of deep learning technologies for prediction of human biological age using multiple data types, and transferred learning from aging into disease, target identification, and signalling pathway modelling.

Metabolic Stability 92

Metabolic Stability Clinical Trials Small Molecule Therapies 92

The Pharma Data

MARCH 28, 2022

We are incredibly grateful for the selfless commitment of the individuals with ALS who participated in the study, and the community’s dedication to advancing research for this devastating disease,” said Toby Ferguson, M.D., Biogen Inc. Nasdaq: BIIB) and Ionis Pharmaceuticals, Inc.

RNA 52

RNA Therapies Disease Biosimilars 52

NIH Director's Blog: Drug Development

OCTOBER 30, 2018

MicroED, the cryo-EM approach generating so much excitement in this report, was first introduced in 2013 by Tamir Gonen, an investigator at the Howard Hughes Medical Institute, who is now at the University of California, Los Angeles (UCLA) [3]. 2013 Nov 19;2:e01345. [4] Angew Chem Int Ed Engl. 2018 Oct 16. May 15, 2018.

Small Molecule 52

Small Molecule Science Drug Development Organic Chemistry 52

Drug Target Review

JULY 5, 2024

Since brain organoids can be derived from either diseased or healthy patients, they can recapitulate human (patho)physiology making them a better choice compared to mammalian cell systems that often fail to recapitulate the human phenotype. 502:327-332 (2013). Induction of myelinating oligodendrocytes in human cortical spheroids.

Drugs 64

Drugs Targeted Protein Degradation Disease FDA Approval 64

Vial

JUNE 12, 2024

In clinical trials, PROs may assess disease progression, consequence(s) of the intervention being studied, functional status, and social, mental, and emotional limitations. PROs can be disease-specific, condition-specific, or generic. Generic PROs are used for any disease or population. For HF, Savarese et al.

Clinical Trials 52

Clinical Trials Trials FDA Clinical Research 52

Drug Target Review

FEBRUARY 28, 2024

Human γδ TCR repertoires in health and disease. Cell Mol Immunol 10(1):21-9 (2013). Increased frequency of TCR gamma delta + T cells in disease-free survivors following T cell-depleted, partially mismatched, related donor bone marrow transplantation for leukemia. Cells 9(40):800 (2020). Holtmeier W, Kabelitz D.

Therapies 105

Therapies Engineering Molecular Biology Science 105

The Pharma Data

SEPTEMBER 15, 2020

“ Amgen addresses important scientific questions to advance care and improve the lives of patients with serious diseases, including oncology, inflammation and cardiometabolic diseases, among others,” said Flavius Martin , vice president of Oncology, Inflammation and Site Head at Amgen South San Francisco.

Targeted Protein Degradation 52

Targeted Protein Degradation Molecular Biology Science Small Molecule 52

LifeSciVC

OCTOBER 10, 2024

Relatlimab has been in the clinic since late 2013, where similar questions have existed about the mechanism due to an absence of disclosures of single-agent pharmacodynamic and efficacy data. The second presentation of note was the Phase 2 data for relatlimab , an inhibitor of LAG3, another checkpoint receptor, in patients with NSCLC.

Therapies 66

Therapies Clinical Development Pharmacokinetics Treatment 66

The Pharma Data

OCTOBER 6, 2021

In 2013, Janssen collaborated with Professor Johan Neyts and Suzanne Kaptein at the KU Leuven Rega Institute and Patrick Chaltin at Centre for Drug Design and Discovery (CD3), as well as their respective teams, to identify a compound series capable of inhibiting the virus in lab-grown cells and animals. Janssen Pharmaceutica, N.V.

Virus 52

Virus Clinical Development Science Disease 52

The Pharma Data

JANUARY 4, 2021

was granted with the “Breakthrough Therapy Designation Drug” by the Center for Drug Evaluation (CDE) and currently enter a phase III clinical trial for treatment of patients with small cell lung cancer (SCLC) with disease progression or recurrence after two lines of prior systematic chemotherapy. SHENZHEN, China , Jan.

Therapies 40

Therapies Clinical Trials Drug Development Drugs 40

H1 Blog

NOVEMBER 29, 2023

The initial report, which came out In 2013 from PhRMA/EFPIA, recognized the importance of data sharing and supported initiatives to enhance clinical trial data transparency and promote scientific advancements. Case Study: Equitable Clinical Trial Access for Women, Minorities Among Cardiovascular Disease in the U.S.

Clinical Trials 59

Clinical Trials Trials Drug Development Treatment 59

Broad Institute

AUGUST 2, 2023

The Sabatini Lab focuses on the development and regulation of synapses in the brain and the relationship of these processes to behavior and disease. Helsinki Center of Economic Research, Helsinki 2013). He held an Academy of Finland professorship for 2013-2017. Bernardo Sabatini, MD, PhD in his lab at Harvard Medical School.

Medical Schools 52

Medical Schools Disease Science International 52

Agency IQ

JULY 13, 2023

PAHPA has been reauthorized several times since its original passage, including as the Pandemic and All-Hazards Preparedness Reauthorization Act of 2013 (PAHPRA) and the Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2019 (PAHPAIA). In the 2013 version, the second “P” stood for “Preparedness.”

FDA 40

FDA Packaging Laboratories Testimonials 40

The Pharma Data

JANUARY 21, 2021

where he developed therapeutics to treat orphan eye diseases. Among his earlier leadership roles in the biotech, pharmaceutical and medical device industries, Caggiano directed the divestiture of Allergan’s LAP-BAND to Apollo Endosurgery in 2013. Additionally, Viridian named Barrett Katz as its chief medical officer.

Laboratories 52

Laboratories Pharmaceuticals Clinical Development Engineering 52

Broad Institute

JANUARY 14, 2025

By Allessandra DiCorato January 14, 2025 Credit: Maria Nemchuk, Broad Communications Eric Minikel and Sonia Vallabh run a lab with a singular focus: preventing and treating prion disease within their lifetime. Its a huge privilege to have the opportunity to point these powerful new tools at our disease.

Disease 144

Disease DNA Protein Production Treatment 144

The Pharma Data

SEPTEMBER 7, 2020

“As a global leader in neuroscience, we have been committed to bringing life-changing therapies to people living with diseases like MS for more than 75 years,” said Estelle Vester-Blokland, Global Head Neuroscience Medical Affairs, Novartis Pharmaceuticals. MS, which affects approximately 2.3

Therapies 52

Therapies Treatment Clinical Trials Disease 52

LifeSciVC

OCTOBER 13, 2022

By Deanna Petersen, CBO of AVROBio, as part of the From the Trenches feature of LifeSciVC Gene therapy’s tremendous potential to transform the treatment of both rare and common diseases has been understood for decades. But few may appreciate how imminently that revolution is upon us. million price.

Therapies 40

Therapies Disease Treatment Marketing 40

The Pharma Data

SEPTEMBER 10, 2021

More than 20 abstracts across disease states, including Parkinson’s disease, spasticity and cervical dystonia, will be presented. “Our research presented at MDS 2021 builds upon our expertise in neuroscience and reinforces our mission to advance the standards of care for people living with these debilitating diseases.”

Doctors 52

Doctors Clinical Trials Disease Treatment 52

The Pharma Data

MARCH 25, 2021

OA is a chronic, progressive and disabling disease of the joint that is a leading cause of chronic pain. In 2013, Pfizer and Lilly entered into a collaboration to develop and commercialize tanezumab. About Osteoarthritis. About the Pfizer-Lilly Alliance. If approved, the companies will jointly commercialize tanezumab in the U.S.

Treatment 52

Treatment FDA Therapies Licensing 52